Evidence map›Paper›PMID 25187515›Full record

ArticleThe Journal of biological chemistry2014

Selective impairment of a subset of Ran-GTP-binding domains of ran-binding protein 2 (Ranbp2) suffices to recapitulate the degeneration of the retinal pigment epithelium (RPE) triggered by Ranbp2 ablation.

Hemangi Patil, Arjun Saha, Eugene Senda, Kyoung-in Cho, MdEmdadul Haque, Minzhong Yu, Sunny Qiu, Dosuk Yoon, Ying Hao, Neal S Peachey and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Nuclear Pore Dysfunction in Neurodegeneration.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  3. Article
  4. Review
  5. Article
  6. Ran GTPase: A Key Player in Tumor Progression and Metastasis.Frontiers in cell and developmental biology · 2020
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Hemangi PatilFrom the Departments of Ophthalmology and.
Arjun SahaFrom the Departments of Ophthalmology and.
Eugene SendaFrom the Departments of Ophthalmology and.
Kyoung-in ChoFrom the Departments of Ophthalmology and.
MdEmdadul HaqueFrom the Departments of Ophthalmology and.
Minzhong Yuthe Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195.
Sunny QiuFrom the Departments of Ophthalmology and.
Dosuk YoonFrom the Departments of Ophthalmology and.
Ying HaoFrom the Departments of Ophthalmology and.
Neal S Peacheythe Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, the Research Service, Cleveland Veterans Affairs Medical Center, Cleveland, Ohio 44106, and the Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio 44195.
Paulo A FerreiraFrom the Departments of Ophthalmology and Pathology, Duke University Medical Center, Durham, North Carolina 27710, paulo.ferreira@duke.edu.
Duke University Hospital · USDuke Medical Center · USCase Western Reserve University · USCleveland Clinic · US

Funding

VISION RESEARCHP30EY005722 · NEI · DUKE UNIVERSITY · PI Vadim Y Arshavsky · 1985 to 2026
$19.3M
Project 2 - neurotransgenic core - Neuroscience Infrastructure at Duke UniversityP30NS061789 · NINDS · DUKE UNIVERSITY · PI MCNAMARA, JAMES O. · 2008 to 2013
$3.4M
Genetic and Molecular Analyses of Protein Biogenesis in the NeuroretinaR01EY019492 · NEI · DUKE UNIVERSITY · PI FERREIRA, PAULO A · 2010 to 2013
$1.5M
Genetic and Molecular Dissection of RanBP2-Mediated RanGTPase FunctionsR01GM083165 · NIGMS · DUKE UNIVERSITY · PI FERREIRA, PAULO A · 2010 to 2013
$1.4M
NEI NIH HHS 2P30-EY005722NEI NIH HHS EY019492NEI NIH HHS P30 EY005722NEI NIH HHS R01 EY019492NIGMS NIH HHS GM083165NIGMS NIH HHS GM083165-04S1NIGMS NIH HHS R01 GM083165NINDS NIH HHS 5P30NS061789NINDS NIH HHS P30 NS061789
6 · The paper itself

Abstract

Retinal pigment epithelium (RPE) degeneration underpins diseases triggered by disparate genetic lesions, noxious insults, or both. The pleiotropic Ranbp2 controls the expression of intrinsic and extrinsic pathological stressors impinging on cellular viability. However, the physiological targets and mechanisms controlled by Ranbp2 in tissue homeostasis, such as RPE, are ill defined. We show that mice, RPE-cre::Ranbp2(-/-), with selective Ranbp2 ablation in RPE develop pigmentary changes, syncytia, hypoplasia, age-dependent centrifugal and non-apoptotic degeneration of the RPE, and secondary leakage of choriocapillaris. These manifestations are accompanied by the development of F-actin clouds, metalloproteinase-11 activation, deregulation of expression or subcellular localization of critical RPE proteins, atrophic cell extrusions into the subretinal space, and compensatory proliferation of peripheral RPE. To gain mechanistic insights into what Ranbp2 activities are vital to the RPE, we performed genetic complementation analyses of transgenic lines of bacterial artificial chromosomes of Ranbp2 harboring loss of function of selective Ranbp2 domains expressed in a Ranbp2(-/-) background. Among the transgenic lines produced, only Tg(RBD2/3*-HA)::RPE-cre::Ranbp2(-/-)-expressing mutations, which selectively impair binding of RBD2/3 (Ran-binding domains 2 and 3) of Ranbp2 to Ran-GTP, recapitulate RPE degeneration, as observed with RPE-cre::Ranbp2(-/-). By contrast, Tg(RBD2/3*-HA) expression rescues the degeneration of cone photoreceptors lacking Ranbp2. The RPE of RPE-cre::Ranbp2(-/-) and Tg(RBD2/3*-HA)::RPE-cre::Ranbp2(-/-) share proteostatic deregulation of Ran GTPase, serotransferrin, and γ-tubulin and suppression of light-evoked electrophysiological responses. These studies unravel selective roles of Ranbp2 and its RBD2 and RBD3 in RPE survival and functions. We posit that the control of Ran GTPase by Ranbp2 emerges as a novel therapeutic target in diseases promoting RPE degeneration.

Indexed as

Gene DeletionAnimalsCapillariesCell ProliferationCell SurvivalChromosomes, Artificial, BacterialDisease ProgressionElectrophysiological PhenomenaIntegrasesMiceMice, TransgenicMolecular ChaperonesMutationNuclear Pore Complex ProteinsProtein Structure, TertiaryRetinal Pigment EpitheliumCre recombinaseIntegrasesMolecular ChaperonesNuclear Pore Complex Proteinsran-binding protein 2Cell BiologyCell DeathCellular RegulationElectrophysiologyEpithelial CellGene KnockoutMicroscopic ImagingProteostasisRNA RegulationTransgenic Mice

Identifiers

PMID25187515
PMCPMC4207991
OpenAlexW2018200868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.